Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0060 • ACR Convergence 2021
Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
Abha Singh¹, Jessica Murillo Saich², Roxana Coras³, Julio Ramirez⁴, Eric Chang², Raquel Celis⁵, Aaron Armando², Oswald Quehenberger², Arthur Kavanaugh², Juan D Cañete⁶ and Monica Guma⁷, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ⁴Arthritis Unit, Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Oxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation. Oxylipins derived from n-6 PUFA precursors, such as arachidonic acid (AA),…
Abstract Number: 0166 • ACR Convergence 2021
Digital Extensor Paratenonitis Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Adrien NZEUSSEU TOUKAP² and Maria S. Stoenoiu³, ¹Rheumatology department, Cliniques Universitaires Saint-Luc, Brussel, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, ³Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor tendon involvement (FEP) or paratenonitis has previously been described by ultrasound (US) in patients suffering from early psoriatic arthritis. Contradictory results were…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0286 • ACR Convergence 2021
Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
Reinder Raadsen¹, Femke Hooijberg¹, Laura Boekel¹, Erik Vogelzang², Gertjan Wolbink¹, Willem Lems³, Arno van Kuijk¹ and Michael Nurmohamed⁴, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³VUmc, Amsterdam, Netherlands, ⁴Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at a higher risk for developing…
Abstract Number: 0460 • ACR Convergence 2021
Single-cell Profiling of B and T Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
Nida Meednu¹, Aaron Wagner², Garett Dunlap³, Fan Zhang⁴, Anna Helena Jonsson⁵, Kevin Wei⁵, Paul Utz⁶, William Robinson⁷, Holden Maecker⁷, Judith James⁸, Joel Guthridge⁸, S. Louis Bridges, Jr.⁹, Vivian Bykerk⁹, Laura Donlin⁹, Susan Goodman⁹, Edward DiCarlo⁹, Christopher Ritchlin¹⁰, Darren Tabechian², James Lederer¹¹, Ellen Gravallese¹², Mandy McGeachy¹³, Gary Firestein¹⁴, David Boyle¹⁵, Peter Gregersen¹⁶, Diane Horowitz¹⁷, Harris Perlman¹⁸, Arthur Mandelin¹⁸, Joan Bathon¹⁹, Laura Geraldino-Pardilla¹⁹, Laura Hughes²⁰, V. Michael Holers²¹, Kevin Deane²², Larry Moreland²¹, Andrew Filer²³, Costantino Pitzalis²⁴, Lindsy Forbess²⁵, Ami Ben-artzi²⁶, Karen Salomon-Escoto²⁷, Soumya Raychaudhuri⁵, Michael Brenner²⁸, Deepak Rao⁵, Andrew McDavid², Jennifer Anolik¹ and Accelerating Medicines Partership (AMP) RA/SLE Network²⁹, ¹University of Rochester Medical center, Rochester, NY, ²University of Rochester, Rochester, NY, ³Harvard University, Somerville, MA, ⁴Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Stanford University, Stanford, CA, ⁷Stanford University, Palo Alto, CA, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹¹Brigham and Women's Hospital and Harvard Medical School, Millis, MA, ¹²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴University of California San Diego, San Diego, CA, ¹⁵University of California San Diego, La Jolla, CA, ¹⁶The Feinstein Institute for Medical Research, Larchmont, NY, ¹⁷Northwell Health, Jericho, NY, ¹⁸Northwestern University, Chicago, IL, ¹⁹Columbia University, New York, NY, ²⁰University of Alabama at Birmingham, Birmingham, AL, ²¹University of Colorado, Denver, CO, ²²University of Colorado Denver, Denver, CO, ²³University of Birmingham, Birmingham, United Kingdom, ²⁴Queen Mary University of London, London, United Kingdom, ²⁵Cedars-Sinai Medical Center, Los Angeles, CA, ²⁶Cedars-Sinai Medical Center, Beverly Hills, CA, ²⁷University of Massachusetts Medical School, Shrewsbury, MA, ²⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁹Brigham and Women's Hospital, Everett, MA
Background/Purpose: B cell and T cell activation pathways in the synovium are an incompletely understood feature of rheumatoid arthritis. In this study, utilizing single cell…
Abstract Number: 0565 • ACR Convergence 2021
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
Brian Breviu¹, Shaobo Pei¹, Matthew Kirkpatrick², Bingjian Feng¹ and Jessica Walsh³, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Depression and anxiety are common in patients with inflammatory arthritis (IA), and have been reported as risk factors for various inflammatory diseases. The study…
Abstract Number: 0588 • ACR Convergence 2021
Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Milena Gianfrancesco¹, Jing Li¹, Clairissa Ja², Andrea Seet¹, Gabriela Schmajuk¹ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC Davis, San Francisco
Background/Purpose: Our understanding of how medications such as biologic disease modifying anti-rheumatic drugs and targeted small molecules (b/tsDMARDs) influence disease activity in RA is based…
Abstract Number: 0685 • ACR Convergence 2021
Adipokines and Loss of Lean Mass Among Patients with Rheumatoid Arthritis
Joshua Baker¹, Jon Giles², Patrick Gould¹ and Patricia Katz³, ¹University of Pennsylvania, Philadelphia, PA, ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of muscle mass and quality that can have significant impacts on physical functioning and quality of life.…
Abstract Number: 0794 • ACR Convergence 2021
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients
Louis Bessette¹, Edward Keystone², Proton Rahman³, Keltie Anderson⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ²Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: The aim of this analysis was to compare between enrolment periods RA treatment outcomes and frequency of treating to target, and to assess the…
Abstract Number: 0811 • ACR Convergence 2021
Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis
Julie Gandrup, Sabine N van der Veer, John McBeth and Will Dixon, University of Manchester, Manchester, United Kingdom
Background/Purpose: Flares are an intrinsic part of the rheumatoid arthritis (RA) disease course and may impact clinical and patient outcomes. Severity, frequency and duration of…
Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Line Uhrenholt¹, Robin Christensen², Wilfred K Dinesen³, Caroline Liboriussen³, Stine Andersen³, Lene Dreyer¹, Annette Schlemmer⁴, Ellen-Margrethe Hauge⁵, Conni Skrubbeltrang⁶ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, Randers Regional Hospital, Randers, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Medical Library, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 1014 • ACR Convergence 2021
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Ted Mikuls¹, Rohit Gaurav¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Brianna Shaw¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Carlos Hunter¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In addition to inflammatory arthritis, collagen-induced arthritis (CIA) recapitulates cardinal features of rheumatoid arthritis (RA) including autoreactive T cells, peptidyl-arginine deiminase expression, and citrullination…
Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Sonia Gupta¹, Vinay thallapally², Sarah Aurit², Rouhin sen³ and Joseph Nahas², ¹Creighton University School of Medicine, Omaha, NE, ²Creighton University, Omaha, NE, ³Colorado University Anschutz Medical Campus, Denver, CO
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
Abstract Number: 1206 • ACR Convergence 2021
Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Elisabeth Rasmussen¹, Liv Thiele¹, Kristian Stengaard-Pedersen², Merete Hetland³, Kim Horslev-Petersen⁴, Peter Junker⁵, Mikkel Ostergaard⁶, Aida Hansen¹, Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ⁵Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Odense M, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular synovitis and frequent occurrence of autoantibodies, playing a central role in disease progression. Anti-citrullinated peptide antibodies (ACPA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].